Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
ImmunoPrecise Antibodies Ltd., often referred to as IPA, is a leading biotechnology company headquartered in Canada. Founded in 2010, the company has established itself as a key player in the field of antibody discovery and development, with significant operations across North America and Europe.
Specialising in custom monoclonal antibodies, ImmunoPrecise offers a unique suite of services, including hybridoma development and phage display technologies, which set them apart in the competitive landscape. The company has achieved notable milestones, such as the successful launch of its proprietary antibody discovery platform, enhancing its market position.
With a commitment to innovation and quality, ImmunoPrecise Antibodies Ltd. continues to support the biopharmaceutical industry, providing essential tools for research and therapeutic development.
-21 vs industry average
ImmunoPrecise Antibodies Ltd.’s score of 21 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for ImmunoPrecise Antibodies Ltd. yet.
ImmunoPrecise Antibodies Ltd., headquartered in Canada, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time.
As there are no emissions data or reduction initiatives available, it is important to note that the company may still be in the early stages of developing its climate strategy. In the broader context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting Science-Based Targets (SBTi) to align with global climate goals. However, without specific commitments or data from ImmunoPrecise Antibodies Ltd., it is unclear how they plan to address climate change or carbon emissions in the future.
No climate goals have been disclosed for ImmunoPrecise Antibodies Ltd. yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more